Abstract

Commercialization of a One Step Continuous Synthesis of Flucytosine

Eugene Lottering, CEO, Msizi Pharmaceutical Holdings

The one-step continuous flow synthesis technology for the manufacture of Flucytosine was developed and prototyped in Europe. It is being transferred to South Africa by Msizi Pharmaceutical Holdings (Pty) Ltd a start-up API manufacturing company. Flucytosine is an important anti-fungal that is unavailable in the majority of African countries. However, it is also a key intermediate in the manufacture of some Anti-retroviral APIs currently used in South Africa and on the African continent. Continuous manufacturing via flow chemistry provides South Africa with an opportunity to localize the manufacture of Essential medicine APIs.